Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents

Am J Hematol. 2025 Apr;100(4):708-711. doi: 10.1002/ajh.27591. Epub 2025 Jan 20.

Abstract

Expectation of survival of patients receiving HMA + VEN is influenced by pre-treatment comorbidity burden.

Keywords: AML; acute myeloid leukemia; fitness; low intensity therapy.

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
  • Bridged Bicyclo Compounds, Heterocyclic* / administration & dosage
  • Bridged Bicyclo Compounds, Heterocyclic* / therapeutic use
  • Comorbidity
  • Female
  • Humans
  • Male
  • Middle Aged
  • Sulfonamides* / administration & dosage
  • Sulfonamides* / therapeutic use
  • Survival Rate

Substances

  • venetoclax
  • Bridged Bicyclo Compounds, Heterocyclic
  • Sulfonamides